---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-001666"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:14:41.404655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia receives key patent allowance for LUPKYNIS dosing and PTAB terminates IPR challenge

## Summary
- USPTO allowed patent application 17/713,140 for LUPKYNIS dosing with eGFR, extending protection to 2037.
- PTAB terminated Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036 (Orange Book-listed).
- New patent supplements existing method-of-use patent; Aurinia intends to list it in Orange Book when issued.

## SEC filing metadata
- accession: 0001628280-23-001666
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828023001666/0001628280-23-001666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828023001666/auph-20230124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-001666
- JSON: https://secwatch.observer/filing/0001628280-23-001666.json
- Plain text: https://secwatch.observer/filing/0001628280-23-001666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.